Evidence map›Paper›PMID 35974889›Full record

ArticleQatar medical journal2022

Safety and outcomes of thrombolytic therapy in patients with pulmonary embolism and thrombocytopenia: A systematic review.

Fateen Ata, Wanis Hamad Ibrahim, Mohammad Nasser Affas, Haseeb Ahmad Khan, Hafiz Waqas Younas, Zakaria Maat, Sabah Elshayeb Ali Mohamed, Balqis Daoudi

Open access · diamondAbstract read
In one paragraph

Article in Qatar medical journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 3 countries.

Fateen AtaDepartment of Internal Medicine, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar E-mail: docfateenata@gmail.com; E-mail: FAta@hamad.qa.
Wanis Hamad IbrahimDepartment of Internal Medicine, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar E-mail: docfateenata@gmail.com; E-mail: FAta@hamad.qa.
Mohammad Nasser AffasDepartment of Internal Medicine, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar E-mail: docfateenata@gmail.com; E-mail: FAta@hamad.qa.
Haseeb Ahmad KhanDepartment of Internal Medicine, Nishtar Hospital, Multan, Pakistan.
Hafiz Waqas YounasDepartment of Emergency Medicine, Forth Valley Royal Hospital, Larbert, Scotland, UK.
Zakaria MaatDepartment of Internal Medicine, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar E-mail: docfateenata@gmail.com; E-mail: FAta@hamad.qa.
Sabah Elshayeb Ali MohamedDepartment of Internal Medicine, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar E-mail: docfateenata@gmail.com; E-mail: FAta@hamad.qa.
Balqis DaoudiClinical Pharmacy Department, Hamad Medical Corporation, Doha, Qatar.
Hamad Medical Corporation · QAForth Valley Royal Hospital · GBHamad General Hospital · QANishtar Medical College and Hospital · PK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Thrombolysis is an established therapeutic modality for patients with high-risk (and some selected intermediate-risk) pulmonary embolism (PE) with hemodynamic instability. Physicians sometimes experience cases where both a high-risk PE and thrombocytopenia coexist. Although thrombocytopenia of <  100 × 10

Indexed as

anticoagulationPEplateletsPulmonary embolismThrombocytopeniathrombolysis

Identifiers

PMID35974889
PMCPMC9372479
OpenAlexW4289937910

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.